Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hyloris PharmaceuticalsLTS:0AB6 11 Earnings per Share (Diluted) is €-0.23 as of Dec. 2025. GuruFocus rates LTS:0AB6 with a GF Score™ of 11/100 and a GF Value™ of €9.88 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,157 Biotechnology companies, Hyloris Pharmaceuticals ranks worse than 51.6% on this metric.
During the past 3 years, the average EPS without NRIGrowth Rate was 15.10% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 8.60% per year.
During the past 9 years, Hyloris Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 22.90% per year. The lowest was -28.20% per year. And the median was -20.30% per year.
Hyloris Pharmaceuticals (LTS:0AB6) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Hyloris Pharmaceuticals Earnings per Share (Diluted) Related Terms
Hyloris Pharmaceuticals Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Hyloris Pharmaceuticals's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hyloris Pharmaceuticals Earnings per Share (Diluted) Chart
LTS:0AB6 vs VRTX, REGN, MRNA: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, Hyloris Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hyloris Pharmaceuticals PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's PE Ratio distribution charts can be found below:
* The bar in red indicates where Hyloris Pharmaceuticals's PE Ratio falls into.
Hyloris Pharmaceuticals Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Hyloris Pharmaceuticals's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.23
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of €-0.23 mean?
Hyloris Pharmaceuticals (LTS:0AB6) has a Earnings per Share (Diluted) of €-0.23 as of Dec. 2025. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Hyloris Pharmaceuticals and its competitors. According to the industry distribution chart, Hyloris Pharmaceuticals ranks #597 out of 1157 companies in the Biotechnology industry, placing it in the top 51.6%.
Is Hyloris Pharmaceuticals' Earnings per Share (Diluted) too high?
Hyloris Pharmaceuticals' current Earnings per Share (Diluted) is €-0.23. Based on the distribution chart, Hyloris Pharmaceuticals ranks #597 out of 1157 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Hyloris Pharmaceuticals has a GF Score™ of 11/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hyloris Pharmaceuticals' Earnings per Share (Diluted) compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hyloris Pharmaceuticals ranks #597 out of 1157 companies for Earnings per Share (Diluted). This places Hyloris Pharmaceuticals in the lower half of its industry. The industry median Earnings per Share (Diluted) is 15.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 15.90, based on 1,157 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Hyloris Pharmaceuticals and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 15.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hyloris Pharmaceuticals's current Earnings per Share (Diluted) is €-0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyloris Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals (LTS:0AB6) is currently considered Possible Value Trap. The stock's GF Value™ is €9.88, compared to a current price of €4.25 — trading 57% below its estimated fair value. The current Earnings per Share (Diluted) is €-0.23. Hyloris Pharmaceuticals' overall GF Score™ is 11/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Hyloris Pharmaceuticals (LTS:0AB6), the current Earnings per Share (Diluted) is €-0.23 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hyloris Pharmaceuticals (LTS:0AB6) Overvalued in 2026?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals stock appears to be undervalued.
The current stock price of €4.25 is trading 57% below its estimated GF Value™ of €9.88.
GuruFocus considers Hyloris Pharmaceuticals to be Possible Value Trap.
Key valuation signals for LTS:0AB6:
Earnings per Share (Diluted): €-0.23
GF Value™: €9.88 vs. price of €4.25 (57% below fair value)
No single metric tells the full story. See the LTS:0AB6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.
11GF Score
Get the complete analysis for LTS:0AB6
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0AB6 has been successfully added to your 
